[go: up one dir, main page]

PE20091973A1 - Anticuerpos modificadores de enfermedades cancerosas - Google Patents

Anticuerpos modificadores de enfermedades cancerosas

Info

Publication number
PE20091973A1
PE20091973A1 PE2009000695A PE2009000695A PE20091973A1 PE 20091973 A1 PE20091973 A1 PE 20091973A1 PE 2009000695 A PE2009000695 A PE 2009000695A PE 2009000695 A PE2009000695 A PE 2009000695A PE 20091973 A1 PE20091973 A1 PE 20091973A1
Authority
PE
Peru
Prior art keywords
antibody
isolated
cancer
cancer disease
disease modifying
Prior art date
Application number
PE2009000695A
Other languages
English (en)
Inventor
David S F Young
Helen P Findlay
Susan E Hahn
Lisa A Popp
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20091973A1 publication Critical patent/PE20091973A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE REFIERE A UN ANTICUERPO MONOCLONAL AISLADO, UN ANTICUERPO HUMANIZADO DEL ANTICUERPO MONOCLONAL AISLADO, UN ANTICUERPO QUIMERICO DEL ANTICUERPO MONOCLONAL AISLADO O ANTICUERPOS MODIFICADORES DE ENFERMEDADES CANCEROSAS (CDMAB) DE LOS MISMOS, QUE SE CARACTERIZAN POR LA CAPACIDAD DE INHIBIR COMPETITIVAMENTE LA UNION DE DICHO ANTICUERPO MONOCLONAL AISLADO A SU ANTIGENO OBJETIVO. DICHO ANTICUERPO AISLADO ES CONJUGADO CON PORCIONES CITOTOXICAS COMO UN ISOTOPO RADIACTIVO, ENZIMAS, COMPUESTOS RADIOACTIVOS Y CELULAS HEMATOGENAS. REFIERE TAMBIEN QUE DICHO ANTICUERPO AISLADO ACTIVA EL COMPLEMENTO
PE2009000695A 2008-05-19 2009-05-18 Anticuerpos modificadores de enfermedades cancerosas PE20091973A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5437208P 2008-05-19 2008-05-19

Publications (1)

Publication Number Publication Date
PE20091973A1 true PE20091973A1 (es) 2010-01-15

Family

ID=41339689

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000695A PE20091973A1 (es) 2008-05-19 2009-05-18 Anticuerpos modificadores de enfermedades cancerosas

Country Status (5)

Country Link
US (1) US20090304579A1 (es)
AR (1) AR071847A1 (es)
PE (1) PE20091973A1 (es)
TW (1) TW200948382A (es)
WO (1) WO2009140755A1 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005518393A (ja) * 2001-12-21 2005-06-23 アリアス リサーチ、インコーポレイテッド 個別化抗癌抗体

Also Published As

Publication number Publication date
AR071847A1 (es) 2010-07-21
TW200948382A (en) 2009-12-01
US20090304579A1 (en) 2009-12-10
WO2009140755A1 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
CO6140062A2 (es) Anticuerpos anti-trop-2 humanizados y quiméricos que median citotoxicidad de celulas cancerosas
CL2021002645A1 (es) Anticuerpos anti-muc16-cd3 biespecíficos y conjugados anti-muc16-fármacos. (divisional de solicitud 201900726)
BR112017027498A2 (pt) anticorpo, ácido nucleico, composto, composição, e, método para tratamento de um paciente com uma doença.
CL2017001580A1 (es) Anticuerpo o fragmento de anticuerpo contra cd38 anticuerpo humanizado, conjugado del anticuerpo con un compuesto citotoxico composición farmacéutica con dichos anticuerpos uso de los anticuerpos para tratar cáncer o enfermedad autoinmune método para diagnosticar cáncer polinucleotido vector y célula huésped.
CO2019003923A2 (es) Anticuerpos anti-steap2, conjugados anticuerpo-fármaco, y moléculas de fijación al antígeno biespecíficas que se fijan a steap2 y cd3, y usos de estos
CO6241160A2 (es) Anticuerpos anti-cd44 quiméricos y humanizados que median la citotoxicidad de celulas de cancer
AR096015A1 (es) Conjugados de fármacos con anticuerpos
NI200900022A (es) Anticuerpo especifico de prlr y usos del mismo
EA201100779A1 (ru) Композиции антител к cxcr1 и способы их применения
AR070168A1 (es) Anticuerpos anti-cd79b e inmunoconjugados y metodos de uso de los mismos
ECSP12012138A (es) Anticuerpo monoclonico anti-cd44 que liga el carcinoma escamocelular de cabeza y cuello
AR091702A1 (es) Anticuerpos anti-cd79b e inmunoconjugados
PE20120902A1 (es) Anticuerpos anti-egfl7 humanizados
PE20140806A1 (es) Anticuerpos anti-factor d humanizados y sus usos
CY1119430T1 (el) Anti-s100a7 αντισωματα για τη θεραπευτικη αγωγη και διαγνωση καρκινου
CO6630177A2 (es) Composiciones y métodos para el diagnóstico y tratamiento de tumores
AR115571A1 (es) Conjugados anticuerpo droga para ablación de células madre hematopoyéticas
PE20140756A1 (es) Anticuerpos que se unen a bst1
PE20091973A1 (es) Anticuerpos modificadores de enfermedades cancerosas
BR112021024328A2 (pt) Métodos e composições para tratar doenças autoimunes
PE20091406A1 (es) Anticuerpos modificadores de enfermedades cancerosas
AR131527A1 (es) Anticuerpos anti-b7h3 y métodos de uso
PE20091365A1 (es) Anticuerpos modificadores de enfermedades cancerosas
AR108451A1 (es) Anticuerpos anti-tenascina modificados y métodos de utilización
MX2022008745A (es) Anticuerpos anti-nkp30 y metodos de uso.

Legal Events

Date Code Title Description
FD Application declared void or lapsed